The combined company will be listed on the New York Stock Exchange and sell branded drugs such as Mallinckrodt's Acthar gel and kidney disease therapy Terlivaz as well as Endo's testosterone injection ...

Mallinckrodt manufactures branded drugs like Acthar Gel for autoimmune disorders, as well as a generic oxycodone pain treatment. Endo is best known for making painkiller Percocet, which accounts for ...

Mallinckrodt and Endo, drugmakers with a shared history of bankruptcy and U.S. opioid litigation, will merge in a deal valued at nearly $7 billion to boost scale for selling their branded drugs. Endo ...

Achieved High End of Full-Year Net Sales Guidance Range and Midpoint of Adjusted EBITDA Guidance Range Grew Full-Year Net Sales by 6.1% to $2.0 Billion, with 14.2% Growth in Acthar ® Gel ...

Mallinckrodt Pharmaceuticals and Endo Inc. plan to merge and create a $6.7 billion company in a move that will cut costs and broaden access to patients and new treatments.

View original content to download multimedia:https://www.prnewswire.com/news-releases/mallinckrodt-plc-reports-fourth-quarter-and-fiscal-year-2024-financial-results ...

The company filed for bankruptcy again in 2023 following declining sales of key products. Net sales of the company’s top-selling drug, Acthar – a gel used to treat certain autoimmune and skin diseases ...